Amendment to License Agreement, dated October 31, 2018, by and between Cornell University and Recro Pharma, Inc

Contract Categories: Intellectual Property - License Agreements
EX-10.26 4 reph-ex1026_399.htm EX-10.26 reph-ex1026_399.htm


Exhibit 10.26

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.


395 Pine Tree Road, Suite 310  

Ithaca, New York 14850  

p- 607 ###-###-####

f. 607 ###-###-####


October 31, 2018

Jyrki Mattila, PhD

Executive Vice President of Business Development

Recro Pharma, Inc.

490 Lapp Road, Malvern PA 19355

Email: ***@***


to the License Agreement by and between Recro Pharma, Inc. (hereinafter “LICENSEE”) and Cornell University (“Cornell”), as represented by its Center for Technology Licensing at Cornell University (hereinafter “CTL”) effective June 30, 2017, and amended effective October 24, 2017 (Cornell Contract #C2017-12-10946)

Effective as of the date of the last signature below (“Second Amendment Date”), the undersigned parties agree to hereby modify the License Agreement referenced above as follows:

1)In Paragraph 3.3 Due Diligence, replace (a)(ii) and (a)(iii) with the following:

(ii) [***];

(iii)  [***];

2)These changes do not otherwise change the terms and conditions of the Agreement.






IN WITNESS THEREOF, the parties have caused this instrument to be executed in duplicate as of the Amendment Date written above.


Cornell University


Recro Pharma, Inc.










/s/ Brian J. Kelly, PhD




/s/ G. A. Henwood










Brian J. Kelly, PhD




G.A. Henwood



Director, Technology Licensing




CEO & President










November 29, 2018




November 27, 2018